Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300591 | 0.88 | TSHR (0.41) | MAPTALDH1A1HPGDLMNAPOLB | |
| SCHEMBL11790553 | 0.88 | CA1 (0.46) | CA1CA2CA9MAPTNPC1 | |
| SCHEMBL9949539 | 0.84 | MAPT (0.46) | CA1CA2CA9MAPTNPC1 | |
| SCHEMBL190945 | 0.83 | TSHR (0.58) | CA1CA2CA9MAPTNPC1 | |
| SCHEMBL10015246 | 0.82 | MEN1 (0.48) | CA1CA2HPGDSMN1; SMN2TDP1 | |
| SCHEMBL11508054 | 0.81 | MEN1 (0.46) | NPC1RAB9AALDH1A1LMNAPOLB | |
| SCHEMBL5191765 | 0.81 | CYP3A4 (0.51) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10784381 | 0.81 | LMNA (0.48) | CA1CA2CA9MAPTNPC1 | |
| SCHEMBL4624141 | 0.81 | TSHR (0.56) | CA1CA2CA9MAPTNPC1 | |
| SCHEMBL11806179 | 0.79 | MAPT (0.44) | CA1CA2CA9MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | claimed |
| US-20050009775-A1 | Nucleoside compounds in hcv | GLAXO GROUP LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1404694-A1 | NUCLEOSIDE COMPOUNDS IN HCV | GLAXO GROUP LIMITED (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000713-A1 | NUCLEOSIDE COMPOUNDS IN HCV | GLAXO GROUP LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| US-4144394-A | FLAME RETARDANTS FOR POLYMERS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4134877-A | Flame retardant phosphoramidate compositions | MONSANTO COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4124400-A | Flame retardant polymer compositions | MONSANTO COMPANY (US) | 1978-11-07 | — | — | US | disclosed |
| US-4086302-A | FLAME RETARDANTS | MONSANTO COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4062909-A | FIRE RETARDANTS | MONSANTO COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009775-A1 | Nucleoside compounds in hcv | OR10J3, NR1H3, ORC3 | CA1 4463/4885CA2 4827/4885CA9 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.